Larimar Therapeutics Inc.

2.27
-0.11 (-4.62%)
At close: Apr 23, 2025, 3:59 PM
2.25
-0.54%
Pre-market: Apr 24, 2025, 07:21 AM EDT
-4.62%
Bid 2.19
Market Cap 145.02M
Revenue (ttm) n/a
Net Income (ttm) -80.6M
EPS (ttm) -1.32
PE Ratio (ttm) -1.72
Forward PE -1.17
Analyst Buy
Ask 2.55
Volume 1,277,790
Avg. Volume (20D) 807,667
Open 2.47
Previous Close 2.38
Day's Range 2.18 - 2.50
52-Week Range 1.61 - 11.20
Beta 0.91

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania....

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2014
Employees 65
Stock Exchange NASDAQ
Ticker Symbol LRMR
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for LRMR stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 694.70% from the latest price.

Stock Forecasts
4 months ago
-21.72%
Larimar Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
5 months ago
+8.74%
Larimar Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.